Radiopharm Theranostics Files October 6-K
Ticker: RDPTF · Form: 6-K · Filed: Oct 1, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Radiopharm Theranostics filed its October 6-K, confirming its Australian base and 20-F reporting.
AI Summary
Radiopharm Theranostics Ltd, a foreign private issuer, filed a Form 6-K on October 1, 2025. This filing is for the month of October 2025 and indicates the company will file annual reports under Form 20-F. The company's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Why It Matters
This filing provides routine disclosure for foreign private issuers, informing investors about the company's reporting status and location.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new financial or operational information that would typically impact risk.
Key Players & Entities
- Radiopharm Theranostics Ltd (company) — Registrant
- October 1, 2025 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
- Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (location) — Principal Executive Office
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that provides information which the registrant makes or is required to make public pursuant to the laws of the registrant's home country or jurisdiction of incorporation or organization, or files or is required to file with a stock exchange on which the registrant's securities are traded.
Which annual report form does Radiopharm Theranostics Ltd file?
Radiopharm Theranostics Ltd files its annual reports under cover of Form 20-F.
Where is Radiopharm Theranostics Ltd's principal executive office located?
The company's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
What is the filing date of this Form 6-K?
This Form 6-K was filed as of October 1, 2025.
Is Radiopharm Theranostics Ltd furnishing information under Rule 12g3-2(b)?
No, the registrant indicated 'No' for furnishing information under Rule 12g3-2(b).
Filing Stats: 320 words · 1 min read · ~1 pages · Grade level 19.3 · Accepted 2025-10-01 08:00:24
Filing Documents
- ea0259663-6k_radiopharm.htm (6-K) — 19KB
- ea025966301ex99-1_radiopharm.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001213900-25-094367.txt ( ) — 51KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on October 1, 2025 titled: - “Radiopharm received approval for RAD 202 trial acceleration” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Radiopharm received approval for RAD 202 trial acceleration 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: October 1, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3